A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF
Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES
Primary:
To evaluate efficacy of treatment with anakinra in subjects with CF who are ≥ 12 years of age
by means of lung clearance index (LCI).
Secondary To evaluate safety and tolerability of treatment with anakinra as well as to
investigate further effects of anakinra on lung function and quality of life (QOL) in
subjects with CF.